Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study: A Phase III Trial Randomized Trial (PCS XIV)

NCT07777263 is registered in ClinicalTrials.gov with Dr. Tamim Niazi as lead sponsor.

NCT NCT07777263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07777263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study: A Phase III Trial Randomized Trial (PCS XIV)
Lead sponsor
Dr. Tamim Niazi
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2040
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk prostate cancer